Daily Pharma News - 18 October 2026

Welcome to PharmacoLearn's daily roundup of the most important pharmaceutical and healthcare news for pharmacy students in India. Today's top stories span drug price regulation in India, the Ayush intellectual property boom, pharmacy education expansion in Tamil Nadu, biopharmaceutical innovation in China, infectious disease surveillance in Russia, and two landmark US FDA approvals.

NPPA caps trade margins on 137 anti-cancer drugs at 30% of MRP from November 9

The National Pharmaceutical Pricing Authority (NPPA) has issued a gazette notification dated 17 October 2026 capping trade margins on 137 non-scheduled anti-cancer drugs at 30% of the maximum retail price (MRP), invoking Para 19 of the Drugs Price Control Order (DPCO) 2013. This is one of the most significant drug price control actions in Indian oncology in recent years, extending price regulation to high-cost cancer medicines that sit outside the National List of Essential Medicines.

The NPPA expects the measure to bring prices down by as much as 70% on some products, and manufacturers must report their revised MRPs within 7 days, with the new prices taking effect on 9 November. For pharmacy students, this is a textbook case of how Para 19 of the DPCO - the provision allowing the government to fix prices of non-scheduled drugs in the public interest - works in practice. It is also a reminder of the pharmacist's role in cancer care: with treatment costs being a major barrier to therapy adherence in India, affordable oncology medicines directly translate into better patient outcomes.

Ayush patent filings in India rise eightfold over a decade: Ministry of Ayush PIB release

Data released by the Ministry of Ayush on 16 October 2026 show that annual Ayush patent filings in India have risen from just 63 in FY15 to 590 in FY26 - roughly eightfold growth in a decade. Cumulatively, 4,077 patent filings and 711 grants have been recorded since FY15, with Maharashtra emerging as the leading state at 744 filings and 142 grants.

This surge reflects the growing formalisation of Ayurveda, Yoga, Naturopathy, Unani, Siddha and Homoeopathy research within India's intellectual property framework. For pharmacy students, especially those studying pharmacognosy and natural products, the trend is significant: traditional formulations are increasingly being subjected to modern standards of novelty and inventive step before patent offices. Understanding how traditional knowledge interfaces with patent law - including the safeguards against biopiracy - is becoming an essential part of pharmaceutical education in India.

Tamil Nadu to establish 10 new pharmacy colleges, announces health minister

Tamil Nadu Health Minister Arunraj announced on 17 October 2026 that 10 new pharmacy colleges will be established across the state, aiming to widen access to pharmacy education, particularly for economically disadvantaged students. The announcement also underlined the role of pharmacists in promoting safe and rational medicine use.

Tamil Nadu already hosts some of India's strongest pharmacy institutions, and the expansion signals the state's intent to match pharmacist supply with growing demand in hospital, community and clinical pharmacy services. For aspiring pharmacy students in South India, this development means more seats, more choice of institutions and greater accessibility of B.Pharm and related programmes. It also reinforces a national trend: as India's pharmaceutical industry and healthcare sector expand, the demand for qualified, well-trained pharmacists continues to rise.

China NMPA accepts BLA for Kexing's long-acting G-CSF GB-K02

Kexing Biopharm announced on 16 October 2026 that China's National Medical Products Administration (NMPA) has accepted the biologics licence application (BLA) for GB-K02, a PEGylated long-acting granulocyte colony-stimulating factor (G-CSF). The candidate is designed to reduce the risk of febrile neutropenia in patients receiving myelosuppressive chemotherapy, and now enters formal regulatory review toward commercialisation.

Long-acting G-CSF products, pioneered by drugs like pegfilgrastim, allow once-per-cycle dosing instead of daily injections - a major convenience and compliance advantage in supportive oncology care. For pharmacy students studying biopharmaceutics and biopharmaceuticals, GB-K02 is an instructive example of PEGylation as a half-life extension strategy, and of how China has become a leading originator of follow-on and novel biologics, not merely a manufacturing base.

Russia probes suspected mpox outbreak near Moscow; 5 contacts hospitalised

Russia's consumer protection and public health watchdog Rospotrebnadzor said on 15 October that five contacts of a suspected mpox carrier in the Moscow region had been hospitalised for observation and testing. Contact tracing, disinfection measures and in-house diagnostic testing have been deployed, and no new cases have been confirmed so far.

The incident is a reminder that mpox remains a notifiable infectious disease of concern and that surveillance systems must stay alert even when case counts are low. For pharmacy students, the story ties into lessons on outbreak investigation, the role of diagnostics in confirming or ruling out suspected cases, and the public-health function of contact tracing and isolation protocols - the same principles taught under epidemiology and hospital pharmacy practice.

FDA approves Roche's Enspryng (satralizumab) for thyroid eye disease

The US Food and Drug Administration on 16 October 2026 approved Enspryng (satralizumab), Roche's IL-6 receptor blocker, for adults with thyroid eye disease - the first at-home subcutaneous treatment option for the condition, dosed once every four weeks. The approval is backed by the Phase III SatraGO-1 and SatraGO-2 trials and expands the drug's label beyond neuromyelitis optica spectrum disorder (NMOSD), for which it was approved in 2020.

Thyroid eye disease, associated with Graves' disease, can cause bulging eyes, double vision and vision loss, and treatment options have historically been limited. An at-home self-injectable formulation changes the treatment landscape by reducing hospital visits - an important consideration also in the Indian context, where biologic therapies for autoimmune conditions are gradually becoming more accessible. Pharmacology students should note the mechanism here: IL-6 receptor blockade as a therapeutic strategy in inflammatory autoimmune disease.

FDA approves Opus' Ryzumvi eye drops for presbyopia; Viatris to market in the US

The US FDA on 16 October 2026 approved phentolamine ophthalmic solution 0.75% (Ryzumvi), developed by Opus Genetics, for the treatment of presbyopia in adults - a non-invasive eye drop for near-vision correction that works by pupil constriction. The approval was supported by the VEGA-2 and VEGA-3 trials, and Viatris holds the US commercial rights under a 2022 licence agreement.

Presbyopia affects virtually everyone over 40 as the lens loses elasticity, and current options are largely reading glasses, contact lenses or surgery. Pharmacologically, phentolamine's alpha-adrenergic antagonism reduces pupil diameter, creating a pinhole effect that improves depth of focus. For pharmacy students studying ophthalmic drug delivery and autonomic pharmacology, Ryzumvi is a clean example of how a well-understood drug class can be repurposed into a novel indication through formulation innovation.

Conclusion

Today's news spans the full spectrum of modern pharmacy practice: drug price regulation in India with the NPPA's anti-cancer margin caps, the intellectual property boom in Ayush systems, expanding pharmacy education in Tamil Nadu, biopharmaceutical innovation in China, infectious disease surveillance in Russia, and two significant US FDA approvals in ophthalmology and autoimmune disease. For pharmacy students, the unifying lesson is that pharmacists sit at the intersection of regulation, research, industry and patient care - and staying current with developments across all these domains is what turns a degree into a career.

References

← All daily news